Enodia Therapeutics
targeting translocon protein secretion
- B2B
About Enodia Therapeutics
Developing AI-driven selective small molecule inhibitors targeting translocon to treat cancer, inflammatory diseases, and viral infections by blocking pathological protein secretion.
Key facts
- Industry
- Biotechnology Research
- Company size
- 11–50 employees
- Headquarters
- Paris, Île-de-France, France
- Founded
- 2025
- Revenue
- $5M – $39.7MTamtam estimate
- SIREN
- 941266710
- Website
- enodiatx.com
- linkedin.com/company/enodiatx
Enodia Therapeutics at a glance
Enodia Therapeutics is a B2B company in the Biotechnology Research industry, headquartered in Paris, Île-de-France, France.
Enodia Therapeutics was founded in 2025.
Enodia Therapeutics has 11–50 employees.
Enodia Therapeutics's revenue is $5M – $39.7M (Tamtam estimate).
Enodia Therapeutics's SIREN number is 941266710.
Selling to companies like Enodia Therapeutics?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies